The post-treatment testosterone debate

Conventional wisdom (dating back to the 1940s) has long been that giving testosterone supplements to men who had been treated for prostate cancer is a really bad idea. … READ MORE …

Active surveillance at the EAU annual meeting

Active surveillance and its role in the management of lower-risk forms of prostate cancer, and related issues like MRI scanning, were clearly key topics of attention at the annual meeting of the European Association of Urology in Barcelona over the weekend. … READ MORE …

PREDICT Prostate: a new, sophisticated, prostate cancer prognostic tool

A new paper just published in PLOS Medicine describes the development of a new online tool called PREDICT Prostate. … READ MORE …

Prostvac in the treatment of prostate cancer: an update

As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. … READ MORE …

The Metastatic Prostate Cancer Project: an update

In May 2017 we first let you know about the start-up of the Metastatic Prostate Cancer Project, which was subsequently launched in January 2018. Prostate Cancer International is one of the founding partners — along with the Broad Institute and others — in the development and evolution of this project. … READ MORE …

Low-dose aspirin and prostate cancer-specific mortality

A newly published article — and an associated editorial — in the Annals of Internal Medicine has addressed the possible benefits of taking low-dose aspirin as a method to prevent the progression of newly diagnosed prostate cancer. … READ MORE …

Yes, you are at risk … but risk of exactly what?

An article just published in Urologic Oncology has reported — perhaps not surprisingly — that men who have a single, initial negative biopsy as a consequence of suspicion of prostate cancer are at significant risk for actual diagnosis of prostate cancer over the next 20 years. … READ MORE …